2025 annual financial data
Crescent Biopharma 2025 Operating cash flow margin
Direct answer
Operating cash flow margin was -659.65%.
Operating income was -152,632,000 USD and net income was -153,942,000 USD.
Operating cash flow was -71,532,000 USD.
Get free Crescent Biopharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 10,844,000 USD
- Operating income
- -152,632,000 USD
- Net income
- -153,942,000 USD
- Operating cash flow
- -71,532,000 USD